In a nutshell This study looked at the safety and effectiveness of adding plerixafor (Mozibil) to FLAG-Ida (fludarabine [Fludara], idarubicin [Idamycin], cytarabine [Cytosar-U] and G-CSF) in the treatment of patients with relapsed acute myeloid leukemia. The study found that adding plerixafor to FLAG-Ida treatment (together called PLERIFLAG) was a safe...Read More
Treatment(s) already received-Chemotherapy Posts on Medivizor
Does graft versus host disease affect relapse and survival rates after a stem cell transplant in childhood leukemia?
In a nutshell This study examined the effect of graft versus host disease on relapse rates in children with acute leukemia. This study concluded that graft versus host disease may protect against relapse, but they did not see an effect on survival. Some background One complication following an allogeneic stem cell transplant (transplant using donor...Read More
In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of mantle cell lymphoma. This study concluded that this regimen improved outcomes in patients with mantle cell lymphoma. Some background The standard treatment for mantle cell lymphoma (MCL)...Read More
In a nutshell This study looked at the risk of infection in older patients with indolent non-Hodgkin lymphoma (nHL) treated with bendamustine (Treanda). Researchers concluded that nHL patients treated with bendamustine had increased risk of common bacterial, fungal, and viral infections. Some background Bendamustine is a chemotherapy drug sometimes...Read More
In a nutshell This study examined the effect of dasatinib (Sprycel) in addition to intensive chemotherapy in the treatment of children and young adults with acute lymphoblastic leukemia (ALL). The study concluded that dasatinib with chemotherapy was a safe and effective way to treat ALL. Some background Acute lymphoblastic leukemia (ALL) is a...Read More
In a nutshell This is the first study to look at the development of both secondary cancers and cardiovascular disease (CVD) as late side effects of Hodgkin lymphoma (HL) treatment. The study concluded that there was an increased risk of developing both a secondary cancer and CVD in patients treated before 2000. Some background...Read More
In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...Read More
In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...Read More
In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...Read More
Can chronic myeloid leukemia patients discontinue dasatinib after a year of deep molecular response?
In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...Read More
In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...Read More